Lisa Lynn Decker Igm Biosciences, Inc. (IGMS) insider trading activity

Lisa Lynn Decker is CHIEF BUSINESS OFFICER of IGM Biosciences, Inc.. Currently has a direct ownership of 73,529 shares of IGMS, which is worth approximately $90,440. The most recent transaction as insider was on Mar 14, 2025, when has been sold 4,512 shares (Common Stock) at a price of $1.23 per share, resulting in proceeds of $5,549. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 73.5K

5.78% 3M change

20.53% 12M change

Total Value Held $90,440

Lisa Lynn Decker Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 14 2025	SELL Open market or private sale	$5,549 $1.23 p/Share	4,512 Reduced 5.78%	73,529 Common Stock
Dec 16 2024	SELL Open market or private sale	$7,951 $7.48 p/Share	1,063 Reduced 1.34%	78,041 Common Stock
Sep 13 2024	SELL Open market or private sale	$10,674 $11.54 p/Share	925 Reduced 1.16%	79,104 Common Stock
Jul 19 2024	BUY Grant, award, or other acquisition	-	20,000 Added 19.99%	80,029 Common Stock
Jun 14 2024	SELL Open market or private sale	$7,405 $7.58 p/Share	977 Reduced 1.6%	60,029 Common Stock
Mar 14 2024	SELL Open market or private sale	$16,048 $10.17 p/Share	1,578 Reduced 2.52%	61,006 Common Stock
Mar 13 2024	SELL Open market or private sale	$17,764 $9.88 p/Share	1,798 Reduced 2.79%	62,584 Common Stock
Mar 12 2024	BUY Grant, award, or other acquisition	-	28,750 Added 30.87%	64,382 Common Stock
Dec 13 2023	SELL Open market or private sale	$25,252 $5.78 p/Share	4,369 Reduced 10.92%	35,632 Common Stock
Nov 29 2023	SELL Open market or private sale	$7,327 $6.21 p/Share	1,180 Reduced 2.87%	40,001 11/29/2023
May 23 2023	SELL Open market or private sale	$15,938 $12.66 p/Share	1,259 Reduced 2.97%	41,181 Common Stock
May 15 2023	BUY Grant, award, or other acquisition	$11,253 $11.71 p/Share	961 Added 2.21%	42,440 Common Stock
Apr 18 2023	BUY Grant, award, or other acquisition	-	8,497 Added 17.0%	41,479 Common Stock
Apr 04 2023	BUY Grant, award, or other acquisition	-	16,250 Added 33.01%	32,982 Common Stock
Mar 14 2023	SELL Open market or private sale	$19,872 $18.73 p/Share	1,061 Reduced 5.96%	16,732 Common Stock
Dec 16 2022	SELL Open market or private sale	$47,369 $19.07 p/Share	2,484 Reduced 12.25%	17,793 Common Stock
Nov 23 2022	SELL Open market or private sale	$27,273 $21.68 p/Share	1,258 Reduced 5.84%	20,277 Common Stock
May 24 2022	SELL Open market or private sale	$23,290 $17.1 p/Share	1,362 Reduced 5.95%	21,535 Common Stock
May 13 2022	BUY Grant, award, or other acquisition	$5,113 $12.38 p/Share	413 Added 1.77%	22,897 Common Stock
Mar 15 2022	BUY Grant, award, or other acquisition	-	4,617 Added 17.04%	22,484 Common Stock
Mar 12 2022	BUY Grant, award, or other acquisition	-	7,500 Added 29.57%	17,867 Common Stock
Nov 15 2021	BUY Grant, award, or other acquisition	-	10,000 Added 49.1%	10,367 Common Stock
Nov 15 2021	BUY Grant, award, or other acquisition	$18,713 $50.99 p/Share	367 Added 50.0%	367 Common Stock

Also insider at

BCEL

Atreca, Inc. Healthcare

Chief Business Officer

CMRX

CHIMERIX INC Healthcare

LLD

Lisa Lynn Decker

CHIEF BUSINESS OFFICER

Mountain View, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IGMS shares.

Notify only if

Value

Insider Trading

Get notified when an Igm Biosciences, Inc. insider buys or sells IGMS shares.

Notify only if

Operation

Value

Type

News

Receive news related to IGM Biosciences, Inc.

Track Activities on IGMS

Account